TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Sees Large Growth in Short Interest

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 172,000 shares, a growth of 20.5% from the October 15th total of 142,700 shares. Approximately 5.6% of the shares of the company are short sold. Based on an average daily volume of 71,600 shares, the days-to-cover ratio is presently 2.4 days.

Institutional Investors Weigh In On TFF Pharmaceuticals

A hedge fund recently raised its stake in TFF Pharmaceuticals stock. Westside Investment Management Inc. grew its holdings in shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) by 28.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,491 shares of the company’s stock after purchasing an additional 11,266 shares during the period. Westside Investment Management Inc. owned approximately 1.63% of TFF Pharmaceuticals worth $84,000 at the end of the most recent reporting period. 15.25% of the stock is currently owned by institutional investors and hedge funds.

TFF Pharmaceuticals Trading Down 76.5 %

TFFP traded down $1.22 during trading on Friday, reaching $0.38. 9,167,990 shares of the company were exchanged, compared to its average volume of 94,204. TFF Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $11.00. The firm has a 50 day moving average of $2.02 and a 200 day moving average of $1.99. The stock has a market cap of $1.31 million, a P/E ratio of -0.05 and a beta of 1.32.

TFF Pharmaceuticals (NASDAQ:TFFP) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.22) EPS for the quarter, topping the consensus estimate of ($1.70) by $0.48. TFF Pharmaceuticals had a negative net margin of 1,612.73% and a negative return on equity of 225.15%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.15 million. As a group, analysts forecast that TFF Pharmaceuticals will post -4.28 earnings per share for the current fiscal year.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.